BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22284908)

  • 1. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.
    Schena M; Guarrera S; Buffoni L; Salvadori A; Voglino F; Allione A; Pecorari G; Ruffini E; Garzino-Demo P; Bustreo S; Consito L; Bironzo P; Matullo G
    DNA Repair (Amst); 2012 Apr; 11(4):374-80. PubMed ID: 22284908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.
    Zienolddiny S; Campa D; Lind H; Ryberg D; Skaug V; Stangeland L; Phillips DH; Canzian F; Haugen A
    Carcinogenesis; 2006 Mar; 27(3):560-7. PubMed ID: 16195237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk.
    Qian B; Zhang H; Zhang L; Zhou X; Yu H; Chen K
    Lung Cancer; 2011 Aug; 73(2):138-46. PubMed ID: 21195504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
    Friboulet L; Barrios-Gonzales D; Commo F; Olaussen KA; Vagner S; Adam J; Goubar A; Dorvault N; Lazar V; Job B; Besse B; Validire P; Girard P; Lacroix L; Hasmats J; Dufour F; André F; Soria JC
    Clin Cancer Res; 2011 Sep; 17(17):5562-72. PubMed ID: 21750204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.
    Dong J; Hu Z; Shu Y; Pan S; Chen W; Wang Y; Hu L; Jiang Y; Dai J; Ma H; Jin G; Shen H
    Mol Carcinog; 2012 Jul; 51(7):546-52. PubMed ID: 21739480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-based gene expression signatures in non-small cell lung cancer.
    Zander T; Hofmann A; Staratschek-Jox A; Classen S; Debey-Pascher S; Maisel D; Ansén S; Hahn M; Beyer M; Thomas RK; Gathof B; Mauch C; Delank KS; Engel-Riedel W; Wichmann HE; Stoelben E; Schultze JL; Wolf J
    Clin Cancer Res; 2011 May; 17(10):3360-7. PubMed ID: 21558400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E; Rosell R
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
    Weaver DA; Crawford EL; Warner KA; Elkhairi F; Khuder SA; Willey JC
    Mol Cancer; 2005 May; 4(1):18. PubMed ID: 15882455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of expression of DNA repair proteins in non-small-cell lung cancer].
    Rybárová S; Muri J; Hodorová I; Vecanová J; Benický M; Piovarči D; Janík P; Mihalik J; Mirossay L
    Klin Onkol; 2012; 25(5):370-4. PubMed ID: 23102199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways.
    Saviozzi S; Ceppi P; Novello S; Ghio P; Lo Iacono M; Borasio P; Cambieri A; Volante M; Papotti M; Calogero RA; Scagliotti GV
    Cancer Res; 2009 Apr; 69(8):3390-6. PubMed ID: 19351853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.